A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 168
Summary
- Conditions
- Coronavirus
- COVID-19
- Sars Cov 2
- Severe Acute Respiratory Syndrome
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentMasking: Single (Outcomes Assessor)Masking Description: In the initial part of the dose escalation, participants will be enrolled in sentinel groups in an open manner. In the second part, participants will be enrolled in placebo-controlled groups in an observer-blind manner.Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 60 years
- Gender
- Both males and females
Description
Funded by Coalition for Epidemic Preparedness Innovations (CEPI).
Funded by Coalition for Epidemic Preparedness Innovations (CEPI).
Tracking Information
- NCT #
- NCT04449276
- Collaborators
- Coalition for Epidemic Preparedness Innovations
- Investigators
- Not Provided
Get Well Soon